2’3’-c-di-AM(PS)2 (Rp,Rp) (ammonium salt)

• Product Name Alternative:

  ADU-S100 (ammonium salt); MIW815 (ammonium salt); ML RR-S2 CDA (ammonium salt)

• UNSPSC Description:

  2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium salt (ADU-S100 ammonium salt), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity[1].

• Target Antigen:

  STING

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/2-3-c-di-am-ps-2-rp-rp-ammonium-salt.html

• Purity:

  99.89

• Solubility:

  DMSO : 15 mg/mL (ultrasonic;warming)|H2O : 100 mg/mL (ultrasonic;warming;heat to 60°C)|Methanol : 5 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@@H](O[P@@](OC[C@H]2O[C@@H](N3C(N=CN=C4N)=C4N=C3)[C@H](O)[C@@H]2O5)(S)=O)[C@H](N6C(N=CN=C7N)=C7N=C6)O[C@@H]1CO[P@]5(S)=O.N.N

• Molecular Weight:

  724.60

• References & Citations:

  [1]Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30.Biomaterials. 2018 May;163:67-75. |bioRxiv. 2024 Jan 23.|bioRxiv. 2024 September 20.|bioRxiv. October 23, 2021.|Cancer Cell. 2020 Mar 16;37(3):289-307.e9. |Commun Biol. 2021 Apr 22;4(1):497.|Eur J Med Chem. 2022 Sep 28;243:114796.|J Clin Invest. 2024 Mar 19:e176748.|Mater Today Bio. 2024 Mar 11, 101018.|Nat Commun. 2022 May 31;13(1):3022.|Nature. 2023 Apr;616(7958):806-813.|Patent. US20210322327A1.|Patent. US20220162199A1.|Patent. US20220395465A1.|PLoS One. 2020 Sep 10;15(9):e0237743.|University of Pittsburgh. School of Medicine. 2021 May 14.|Acta Crystallogr D Struct Biol. 2020 Sep 1;76(Pt 9):889-898. |bioRxiv. 2024 May 14.|Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12.|Cancer Res Commun. 2023 Dec 26.|Cell Mol Gastroenterol Hepatol. 2021 Feb 3;S2352-345X(21)00024-2.|Environ Int. 2020 Oct;143:105949.|Eur J Med Chem. 2023 Feb 4;250:115184.|Front Immunol. 2021 Jul.|Front Immunol. 2023 Oct 13:14:1258691.|Immunology. 2022 Jul 20.|Inflamm Res. 2023 Jul 11.|Int J Mol Sci. 2023 Dec 20, 25(1), 86.|J Immunother Cancer. 2019 Sep 18;7(1):252. |J Neuroinflammation. 2023 Apr 30;20(1):101.|Mol Cell Biochem. 2021 Feb;476(2):1015-1024.|Nat Commun. 2023 Mar 13;14(1):1390.|Nat Commun. 2023 Sep 18;14(1):5666.|Nat Nanotechnol. 2021 Sep 30.|Neuron. 2022 Nov 4;S0896-6273(22)00961-8.|Patent. US20200146975A1|Patent. US20210205468A1.|Patent. US20230062932A1.|Purdue University. 2024 Jul 20.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2024 Apr 5.|University of Toronto. 2023 Jun.|Acta Pharm Sin B. 2024 Jun 11.|bioRxiv. 2024 September 07.|Cancer Cell. 2024 May 13;42(5):850-868.e9.|Cell Death Dis. 2022 Jul 28;13(7):653.|Chem Biodivers. 2024 Jul 12:e202401253.|Genes Dis. 2024 Sep 15.|J Autoimmun. 2024 Apr 30:146:103232.|J Immunother Cancer. 2024 Oct 14;12(10):e009803.|Nat Cell Biol. 2024 Jul 30.|Nat Commun. 2023 Oct 2;14(1):6132.|Sci China Life Sci. 2024 Aug 22.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 2

• CAS Number:

  1638750-96-5